Patents Assigned to ADC Therapeutics SA
-
Patent number: 11938192Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).Type: GrantFiled: March 18, 2022Date of Patent: March 26, 2024Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS SAInventors: Jay Marshall Feingold, David Rodney Ungar
-
Patent number: 11813335Abstract: A conjugate of formula (I): Ab-(DL)p??(I) wherein: Ab is an antibody that binds to AXL; DL isType: GrantFiled: September 24, 2021Date of Patent: November 14, 2023Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS SAInventor: Patricius Hendrikus Cornelis Van Berkel
-
Patent number: 11596696Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.Type: GrantFiled: April 20, 2018Date of Patent: March 7, 2023Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITEDInventors: Patricius Hendrikus Cornelis Van Berkel, Lisa Skelton, Francesca Zammarchi, Jay Marshall Feingold, Jens Wuerthner, John Hartley
-
Patent number: 11426467Abstract: The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCS).Type: GrantFiled: June 14, 2018Date of Patent: August 30, 2022Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITEDInventors: Jay Marshall Feingold, Jens Wuerthner
-
Patent number: 11384098Abstract: The present invention relates to pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to an antibody.Type: GrantFiled: February 8, 2018Date of Patent: July 12, 2022Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITEDInventor: Patricius Hendrikus Cornelis Van Berkel
-
Patent number: 11318211Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).Type: GrantFiled: June 14, 2018Date of Patent: May 3, 2022Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITEDInventors: Jay Marshall Feingold, David Rodney Ungar
-
Patent number: 11160872Abstract: A conjugate of formula (T): Ab-(DL)p wherein: Ah is an antibody that hinds to AXL; DL is formula (A).Type: GrantFiled: February 8, 2018Date of Patent: November 2, 2021Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITEDInventor: Patricius Hendrikus Cornelis Van Berkel
-
Patent number: 11084872Abstract: Breast cancer cells lacking ER protein expression, PgR protein expression and/or showing absence of HER2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-KAAG1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to KAAG1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers. The use of antibody conjugates in the treatment of triple-negative breast cancer and/or basal-like breast cancer is disclosed herein.Type: GrantFiled: October 18, 2018Date of Patent: August 10, 2021Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Anna N. Moraitis, Mario Filion
-
Patent number: 10780096Abstract: The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.Type: GrantFiled: November 25, 2015Date of Patent: September 22, 2020Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMITEDInventors: Patricius Henrikus Cornelis Van Berkel, Philip Wilson Howard, John Hartley
-
Patent number: 10597450Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: GrantFiled: November 13, 2017Date of Patent: March 24, 2020Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion
-
Patent number: 10544223Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.Type: GrantFiled: November 21, 2018Date of Patent: January 28, 2020Assignees: ADC THERAPEUTICS SA, MEDIMMUNE LIMTIEDInventors: Patricius Hendrikus Cornelis Van Berkel, Jens Wuerthner, John Hartley, Francesca Zammarchi
-
Patent number: 9855291Abstract: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.Type: GrantFiled: November 3, 2009Date of Patent: January 2, 2018Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
-
Patent number: 9828426Abstract: Novel antibodies and antigen binding fragments that specifically bind to KAAG1 and which may be used in the treatment, detection and diagnosis of cancer comprising KAAG1-expressing cells are disclosed herein. Cells expressing the antibodies and antigen binding fragments as well as methods of detecting and treating cancer using the antibodies and fragments are also disclosed. Cancer indications which may benefit from such treatment or detection include ovarian cancer, renal cancer, lung cancer, colorectal cancer, breast cancer, brain cancer, and prostate cancer, as well as melanomas.Type: GrantFiled: April 25, 2016Date of Patent: November 28, 2017Assignee: ADC Therapeutics SAInventors: Gilles Bernard Tremblay, Anna N. Moraitis, Traian Sulea, Mario Filion